Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

Senhance_featuredImage-1-1200x630.jpg

September 4, 2018 OrthoSpineNews

September 04, 2018

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Eric Smith has been named Chief Commercial Officer, effective August 31, 2018.

In this newly created role, which will report directly to the Chief Executive Officer, Mr. Smith will lead the company’s global commercialization efforts, with a focus on both strategic and tactical execution efforts in sales, upstream and downstream marketing, field clinical support and training with a focus on adoption and clinical excellence.

“We are very excited to have Eric join the TransEnterix team. He brings a wealth of experience commercializing innovative technologies on a global scale,” said Todd M. Pope, Chief Executive Officer of TransEnterix. “As we look to drive widespread adoption of Senhance, we believe that the addition of Eric’s expertise in developing and driving sales and marketing strategies will complement our existing team as we continue to grow and increase our presence in the United States and around the world.”

Mr. Smith brings over two decades of medical technology experience to TransEnterix, with over a decade of that focused on commercial leadership and marketing strategy. Most recently, he was a Vice President, Franchise Leader Acute Care at KCI Corporation, a developer and manufacturer of wound healing products. While at KCI, he was responsible for the development and commercialization of innovative wound-care technologies on a global scale. Prior to joining KCI, Mr. Smith served as Vice President of Global Strategic Marketing at Cordis Corporation, a developer and manufacturer of medical devices for the treatment of coronary and peripheral vascular diseases. He has also held senior positions at Boston Scientific, C.R. Bard and Ernst & Young. He received his Bachelor’s degree from the University of New Hampshire and his MBA from Babson College.

“I am extremely pleased to be joining TransEnterix during such an exciting time in the company’s history,” said Smith. “Senhance is a transformative technology with a large market opportunity, and I look forward to contributing to the company’s success and improving clinical outcomes and patient care through the use of digital laparoscopy.”

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The Company is focused on the commercialization of the Senhance™ Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU and select other countries. For more information, visit www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to the Senhance Surgical System and our current commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Mr. Smith’s expertise in developing and driving sales and marketing strategies will complement TransEnterix’s existing team as TransEnterix continues to group and increase its presence in the United States and around the world and whether Mr. Smith can contribute to TransEnterix’s success and improving clinical outcomes and patient care through the use of digital laparoscopy. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 8, 2018 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

For TransEnterix, Inc.
Investors:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media:
Joanna Rice, +1 951-751-1858
joanna@greymattermarketing.com


ROSA_EN.jpg

August 1, 2018 OrthoSpineNews

MONTPELLIER, France, April 25, 2016 (GLOBE NEWSWIRE) — MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, today announced that it will showcase its ROSA™ robotic surgery systems at the upcoming 84thAmerican Association of Neurological Surgeons (AANS) Annual Meeting, being held April 30 – May 4 in Chicago, IL.

Medtech’s ROSA™ robotic surgery system was developed to assist in a variety of minimally invasive neurological procedures while simultaneously increasing safety and reliability for the surgeon and patient. During the conference, Medtech will demonstrate the ROSA™ system at Booth #5035.

In addition, the ROSA™ robot will be featured at a workshop during the conference. Details of the workshop follow:

Title: 018 Stereotactic and Functional Neurosurgery – Hands-on Workshop
Date: May 1, 2016
Time: 7:30 a.m. – 4:30 p.m.

A ROSA™ robotic surgery system will be highlighted during functional neurosurgery sessions at AANS. The sessions will include discussions highlighting the minimally invasive approach that surgeons are able to utilize through ROSA™. Details of the sessions follow:

Title: Scientific Session III: Stereotactic and Functional
Date: May 2, 2016
Time: 2 p.m. – 5:30 p.m.

Title: AANS/CNS Section on Stereotactic and Functional Surgery
Date: May 3, 2016
Time: 2 p.m. – 5:30 p.m.

About the 2016 AANS Annual Scientific Meeting

Attended by neurosurgeons, neurosurgical residents, medical students, neuroscience nurses, clinical specialists, physician assistants, allied health professionals and other medical professionals, the AANS Annual Scientific Meeting is the largest gathering of neurosurgeons in the nation, with an emphasis on the field’s latest research and technological advances. More than 1,200 scientific abstracts were submitted for the 2015 AANS Annual Scientific Meeting. The scientific presentations accepted for the 2016 event will represent cutting-edge examples of the incredible developments taking place within the field of neurosurgery. Additional information about the 2016 AANS Annual Scientific Meeting and the meeting program can be found here.

About MEDTECH

Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA™,  an innovative technological device devoted to  brain surgery procedures.  ROSA™ has been approved in Europe,  the United States and Canada.

In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.

In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.

In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.

In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.

CONTACT: CONTACT MEDTECH
Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40

INVESTORS
Corinne Puissant
Tel : +33 (0)1 53 67 36 77
cpuissant@actus.fr

PRESS
Alexandra Prisa (EU)          
Tel. : +33(0)1 53 67 36 90 
aprisa@actus.fr                  

Joanna Zimmerman (US)
Tel : +1 646-536-7006
jzimmerman@theruthgroup.com

Ai-OR-1.jpg

July 16, 2018 OrthoSpineNews

July 16, 2018

LONDON–(BUSINESS WIRE)–Digital Surgery, a health tech company shaping the future of surgery through the convergence of surgical expertise and technology, today announced it has developed and successfully demonstrated the world’s first real-time, dynamic artificial intelligence (AI) system designed for the operating room (OR). The company is building the data to power the future of surgery through its world-class and proprietary surgical procedure road maps, which aim to aid the surgical team in the OR, reducing risk and making surgery safer. Digital Surgery is the first patented AI platform bringing this scale of knowledge to the surgical community.

“This is a huge milestone for the future of surgery because it lays the foundation for how AI and computer vision will support surgical teams to deliver safer surgeries. It also enables the next generation of robotic surgery, giving these future systems the capability to function more intelligently and safely,” said Dr. Jean Nehme MD, co-founder and CEO of Digital Surgery. “We have already developed AI algorithms for multiple procedures across bariatrics and other surgical specialties like orthopedics, and our library will continue to grow. With AI, we have the unique ability to scale global surgical best practices.”

More than 5 billion people do not have access to safe surgical care, with surgical knowledge being one of the critical factors that hasn’t been able to scale globally. Addressing this problem will require emerging technologies, including AI, particularly given other technological alternatives, like robotics and telemedicine platforms, require expensive equipment or resources that limit their scalability.

Digital Surgery’s AI platform can provide road maps and act as a navigational system for every OR and surgery center, addressing the countless variables that surgical teams face — from staff turnover, language, culture, tools, resources, to the training and skill level of the surgical team. The AI recognizes what is happening during surgery through a camera view, and cross-checks and correlates the anatomy and actions against the largest library of surgical road maps. The OR team can then see in real time the platform analyzing and predicting next steps.

Quotes from leading surgeons

  • “What Digital Surgery has done with this technology feels like a comparison with the advent of laparoscopy, which was a truly disruptive and groundbreaking revolution and paradigm shift in surgery. This resulted in a huge change in approach from maximally invasive to minimally invasive surgery. In the next five years, I expect there to be a transformation from non-AI to AI supported surgery as common practice, benefiting training, patient safety, data collection and outcomes analysis. This is something my OR teams, clinical teams and I would look forward to and will truly impact patient care.” — Dr. Sanjay Purkayastha, Consultant Laparoscopic, Bariatric & Robotic Surgeon, Imperial College Healthcare NHS Trust and Clinical Senior Lecturer at Imperial College London
  • “The impact of a technology leap like this is astounding. Digital Surgery is creating the technologies that will drive the ‘integrated ORs’ and robotic systems of the future.” — Dr. Daniel Buchbinder, Mount Sinai School of Medicine

The team at Digital Surgery is best known for its leading mobile surgical training app, Touch Surgery, which is embedded in more than 160 residency programs and used by more than 2 million surgeons, healthcare professionals and others globally. Touch Surgery has more than 200 surgical simulations across 14 specialties, and it has been validated by 15 peer-reviewed publications for its approach to virtual surgical training.

About Digital Surgery

Digital Surgery, founded by surgeons for surgeons and healthcare professionals, believes safe surgical care should be accessible for all. Co-founders Dr. Jean Nehme and Dr. Andre Chow set out to shape the future of surgery by building a digital ecosystem that sits at the intersection of surgical expertise and technology. Digital Surgery is comprised of two products, Touch Surgery, the award-winning interactive training platform downloaded more than 2 million times, and GoSurgery, an operating room efficiency platform launching later this year. The company is based in London with teams around the world. For more information, please visit: http://www.digitalsurgery.com.

Contacts

For Digital Surgery
Elizabeth Soares
415-583-4433
elizabeth@brewpr.com

(Photo: Business Wire)


Phil_Bradshaw-1.jpg

March 5, 2018 OrthoSpineNews

March 05, 2018

LONDON–(BUSINESS WIRE)–Intuitive Surgical has named Phil Bradshaw as its first General Manager in the United Kingdom and Ireland (UK&I). Mr. Bradshaw will direct business strategy and operations for the company in these countries.

Intuitive pioneered the field of robotic-assisted, minimally invasive surgery with the creation of its da Vinci Surgical System. Now on its fourth-generation system, the Silicon Valley, California-based company has seen more than five million robotic-assisted surgical procedures performed worldwide, and the da Vinci Surgical Systems’ benefits explored in more than 15,000 peer-reviewed scientific publications to-date.

“Our commitment to the UK & Ireland has been increasing since we entered these markets ten years ago. Phil’s deep knowledge of the medical device industry and his enthusiasm for continued innovation in the UK and Irish markets, expands that commitment,” said Dr. Gary Guthart, CEO of Intuitive. “British surgeons have been at the forefront of driving innovation and improvements in patient care and economic value to the NHS using da Vinci robotic systems, where patients can recover and return home more quickly, saving the healthcare system money,” he added.

Mr. Bradshaw brings nearly three decades of experience in the medical device field working for market-leading companies, and more than eight years of general management experience in the UK and European markets. “Intuitive’s impressive experience and track record of working with surgeons to provide continuous developments in robotic-assisted surgery in the UK and Ireland was very important to me,” said Bradshaw. “The company’s commitment to ensuring that robotic-assisted surgery becomes a standardised option for surgeons in an increasing number of indications, will allow me to serve as a champion for increased patient access here in the UK and Ireland,” he continued.

Before joining Intuitive Surgical, Mr. Bradshaw worked at Medtronic as Strategic Alliance Director for EMEA within the Integrated Health Solutions Division. Prior to Medtronic, he established the Head & Neck Division at Stryker UK, working in the Neurosurgical and Cranio-maxillio facial market. Additionally, Mr. Bradshaw spent 18 years with Synthes, a medical device company specialising in orthopaedics, where he fulfilled a variety of graduated sales and marketing positions, including GM roles in both the UK and Portugal.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, California, is the pioneer in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets the da Vinci Surgical System. The Company’s mission is to make surgery more effective, less invasive and easier on surgeons, patients and their families.

About the da Vinci Surgical System

There are several models of the da Vinci Surgical System. The da Vinci Surgical Systems are designed to help surgeons perform minimally invasive surgery. da Vinci Systems offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.

© 2018 Intuitive Surgical, Inc. All rights reserved. Intuitive Surgical®da Vinci®da Vinci S®da Vinci® Sida Vinci Xi®da Vinci X®, OnSite® and EndoWrist® are trademarks or registered trademarks of Intuitive Surgical, Inc.

For more information, please visit the company’s web site at www.intuitivesurgical.com.

Important Safety Information

Serious complications may occur in any surgery, including da Vinci® Surgery, up to and including death. Risks include, but are not limited to, injury to tissues and organs and conversion to other surgical techniques. If your doctor needs to convert the surgery to another surgical technique, this could result in a longer operative time, additional time under anesthesia, additional or larger incisions and/or increased complications. Individual surgical results may vary. Patients who are not candidates for non-robotic minimally invasive surgery are also not candidates for da Vinci® Surgery. Patients should talk to their doctors to decide if da Vinci®Surgery is right for them. Patients and doctors should review all available information on non-surgical and surgical options in order to make an informed decision. Please also refer to www.daVinciSurgery.com/Safety for Important Safety Information.

Contacts

For Intuitive Surgical:
JPA Health Communications
Kate Perry, 020 3884 0650
isipr@jpa.com


download-9-1.jpg

February 20, 2018 OrthoSpineNews

PARISFeb. 20, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced today the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution. This proprietary technology is currently in early-stage development for total and partial knee replacement, and the Johnson & Johnson Medical Devices Companies plan to broaden its application for a range of orthopaedic surgery procedures.

The goal is to build a next-generation robotic-assisted orthopaedic surgery solution that is cost-effective, time-efficient, and user-friendly in a variety of care settings. Orthotaxy’s technology will be a critical part of a complete orthopaedic solution that uses enabling technologies to personalize procedures, optimize surgery and bring value to customers and patients. Founded by Stéphane Lavallée, a robotics entrepreneur, Orthotaxy designs and develops computer-assisted platforms.

“Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopaedics platform, delivering value to patients, physicians and healthcare providers across the episode of care,” said Ciro Rӧmer, Company Group Chairman of DePuy Synthes, the orthopaedics business of Johnson & Johnson. “The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction.”

This acquisition underscores the companies’ commitment in building an innovative and comprehensive digital surgery platform that brings value to customers and improves the standard of care for as many patients as possible. Moving forward, Johnson & Johnson Medical Devices Companies will focus on digital technology solutions that expand beyond providing best-in-class products to transformative solutions across the full continuum of care.

Financial terms of the transaction will not be disclosed.

About DePuy Synthes

DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

About the Johnson & Johnson Medical Devices Companies

The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs, and research and development capabilities in surgical technology, orthopedics, cardiovascular, and specialty solutions with an offering directed at delivering clinical and economic value to healthcare systems worldwide.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Orthotaxy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Apsis, DePuy Synthes, the Johnson & Johnson Medical Devices Companies, and Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the acquisition may not be realized or may take longer to realize than expected; challenges inherent in product research and development, especially at an early stage of the development program, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; competition, including technological advances, new products and patents attained by competitors; challenges to patents; and changes to applicable laws and regulations, including tax laws and global health care reforms. In addition, there are risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the technology, operations and employees of Orthotaxy, as well as the ability to ensure continued development of Orthotaxy’s products. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under “Item 1A. Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including under the caption “Cautionary Note Regarding Forward-Looking Statements,” and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

 

SOURCE Johnson & Johnson Medical Devices Companies


TransEnterix_Logo-1-ABC-2-e1518027942434.jpg

February 7, 2018 OrthoSpineNews

February 07, 2018

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer will present at the RBC Capital Markets 2018 Global Healthcare Conference at The Lotte New York Palace Hotel in New York, New York. The presentation is scheduled to take place at 2:05 PM Eastern, February 21, 2018.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at http://ir.transenterix.com/events.cfm. A replay of the webcast will be archived on the website for approximately 90 days.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The Senhance Surgical Robotic System is available for sale in the US, the EU and select other countries. For more information, visit the TransEnterix website at www.transenterix.com.

Contacts

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
Joanna Rice, + 1 951-751-1858
joanna@greymattermarketing.com


1-5-1.jpg

January 19, 2018 OrthoSpineNews

JACKSON, Mich.Jan. 19, 2018 /PRNewswire/ — Henry Ford Allegiance Health is the first in Michigan to offer patients the advantages of the ExcelciusGPSTM surgical system. Innovative designs like the ExcelciusGPS are revolutionizing minimally invasive spine surgery and optimizing patient care by combining the benefits of navigation and robotics into one technology. This technology is designed to increase safety for patients and accuracy for their surgeons.

“Robot-assisted surgery is a new, emerging area that will become the standard in care,” said Henry Ford Allegiance Health neurosurgeon Frank La Marca, MD. “At Henry Ford Allegiance Health, we are committed to providing the highest quality of care for our spine surgery patients. We are excited to offer our patients the advantages of the Excelcius system, which allows us to perform minimally invasive procedures which may result in less blood loss, less muscle damage and a potentially faster recovery.”

One of the advantages of the ExcelciusGPS system is the inclusion of a GPS 3-D guidance system, designed to improve accuracy and optimize patient care by combining robotics with navigation, much like the GPS in a car. This advanced technology allows a neurosurgeon to place screws and implants in a very precise fashion while seeing exactly where to place their instruments in real-time.

Henry Ford Allegiance neurosurgeon Azam Basheer, MD, said, “The GPS navigation gives me continuous feedback and allows me to see everything in real time. Now, my colleagues and I can preprogram coordinates, so the robotic arm can assist in guiding us to precise locations in the patient’s spine. The result is safer, faster surgery with less radiation exposure and less need to reposition my patient.”

“Another advantage of ExcelciusGPS is that it allows us to make even safer, more consistent and smaller incisions,” said Henry Ford Allegiance neurosurgeon Armitraj Loganathan, MD. “This is valuable because it promotes healing and lessens scarring.”

About Henry Ford Allegiance Health
Henry Ford Allegiance Health (HFAH) is a 475-bed health system in Jackson, Michigan. HFAH complements traditional acute care services with mission-based services to support patient care across the continuum at every stage of life. With its Level II Trauma Center, Henry Ford Allegiance Health provides comprehensive care for severely injured patients. As a teaching hospital, Henry Ford Allegiance Health continually looks to the future with its Center for Health Innovation & Education and Graduate Medical Education program. Through its Health Improvement Organization (HIO), HFAH is also a national leader in forming community partnerships that innovatively address regional wellness and prevention needs. Visit HenryFordAllegiance.com to learn more.

About Henry Ford Health System
Henry Ford Health System (HFHS) is a six hospital system headquartered in Detroit, Michigan. HFHS is one of the nation’s leading comprehensive, integrated health systems, recognized for clinical excellence and innovation. It provides health insurance and health care delivery, including acute, specialty, primary and preventive care services backed by excellence in research and education. HFHS is a 2011 Malcolm Baldrige National Quality Award recipient. Visit henryford.com to learn more.

SOURCE Henry Ford Allegiance Health

PHOTO: Henry Ford Allegiance Health neurosurgeons Azam Basheer, MD, (left) and Amritraj Loganathan, MD, with the ExcelciusGPS robot

Related Links

http://HenryFordAllegiance.com


1-3-1.jpg

January 17, 2018 OrthoSpineNews

BALTIMOREJan. 17, 2018 /PRNewswire/ — Surgeons at The Johns Hopkins Hospital have for the first time used a real-time, image-guided robot to insert screws into a patient’s spine, alleviating her from severe pain and improving her mobility.

“People get excited when they realize that there are new potential interventions and strategies to help them get better, faster,” says Nicholas Theodore, M.D., professor of neurosurgery at the Johns Hopkins University School of Medicine and director of the Neurosurgical Spine Center of Johns Hopkins Medicine. “We are really excited to be able to offer this to our patients.”

The first patient to go through this new procedure had a spine injury from a fall at home. She agreed to the new robotic surgery, in part, because it aims to be 100 percent accurate.

Current image-guided surgical procedures require the surgeon to look back and forth between the patient and an image, which causes imperfection of screw placement. While oftentimes these placements are “good enough,” it wasn’t good enough for Theodore, who invented the robot and maintains a financial interest in the technology.

This new robot “marries” a CT scan of the patient with the actual patient, allowing the surgeon to point to a spot on the CT scan and tell the robot to aim for that same spot. Connected to a camera, which itself reads landmarks on the patient, the robot is able to process what the camera “sees” with the CT image in real time. The biggest fear in this type of procedure is movement—what if the patient breathes or otherwise moves slightly—but this robot can sense changes in position and adjust accordingly.

After the surgery “I felt better right away. It was amazing,” said the patient in a video testimonial.

Spine surgery is used to treat conditions that include degenerative disease, spine tumors and trauma. According to a 2015 study, traffic accidents and falls are the leading cause of spinal injuries in the United Arab Emirates.

Theodore will be a featured speaker during the Pediatrics and Orthopaedics conferences at Arab Health, in Dubai, and is available for in person interviews on Sunday, January 28th.

Media contact: Alsy Acevedo rel=”nofollow”>aaceved5@jhmi.edu, +1 410-446-1750.

Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is an $8 billion integrated global health enterprise and one of the leading academic health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM’s vision, “Together, we will deliver the promise of medicine,” is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and 40 primary and specialty care outpatient sites under the umbrella of Johns Hopkins Community Physicians. JHM extends health care into the community and globally through Johns Hopkins Home Care Group, Johns Hopkins Medicine International and Johns Hopkins HealthCare. The Johns Hopkins Hospital, opened in 1889, has been ranked #1 in the nation by U.S. News & World Report for 22 years of the survey’s 28-year history. For more information about Johns Hopkins Medicine; its research, education and clinical programs; and for the latest health, science and research news, visit www.hopkinsmedicine.org.

Photo – https://mma.prnewswire.com/media/628191/Johns_Hopkins_Medicine_Nicholas_Theodore_Surgery.jpg


Senhance_featuredImage-1-e1515425727684.jpg

January 8, 2018 OrthoSpineNews

January 08, 2018

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today provided a year-end corporate update.

“2017 was a transformational year for TransEnterix that included the commencement of U.S. Senhance commercialization and progression towards the global commercialization of SurgiBot,” said Todd M. Pope, President and CEO at TransEnterix. “We are very excited about the opportunity that lies ahead in 2018 as we look to build upon our momentum and drive the global adoption of the Senhance.”

Senhance System Revenue

During the quarter ending December 31, 2017, the Company sold two Senhance Systems for total revenue of approximately $3.3 million. Total 2017 revenue is approximately $7.0 million, a 360% increase over 2016, representing a total of five Senhance Systems: Europe (two), Asia (two, including one sale for which the revenue was not recognized in 2017) and the United States (one).

The company currently has received one European Senhance System order that it expects to deliver and recognize revenue for in the quarter ending March 31, 2018.

Product Portfolio

During 2017, the company completed the following product portfolio initiatives:

  • Obtained Senhance System FDA 510(k) clearance for use in colorectal and gynecologic laparoscopic surgery
  • Obtained CE mark and began commercializing the world’s first robotic micro-laparoscopic (3 millimeter) instruments
  • Expanded list of compatible visualization and fluorescence systems to include systems from Stryker, Novadaq (Stryker), Conmed and Richard Wolf
  • Filed approximately 40 new US patent applications. The Company’s patent portfolio now includes approximately 93 issued patents, 25 of which are US Patents, as well as approximately 92 pending applications, 54 of which are US applications.

The Company expects to complete the following product portfolio initiatives in 2018:

  • Expand the Senhance System US FDA clinical indications to include hernia and gallbladder, doubling the total addressable market
  • Launch new ultrasonic energy device
  • Launch new five-millimeter articulating instrument platform

SurgiBot Global System Agreement

On December 18, 2017, the Company announced that it had entered into an agreement with Great Belief International Limited (GBIL) to advance the SurgiBot System towards global commercialization.

The agreement provides the Company with proceeds of at least $29 million, of which $7.5 million was received in December of 2017. An additional $7.5 million is expected to be received by March 31, 2018, including a $3.0 million equity investment at $2.33 per share. The remaining $14 million, representing minimum royalties, will be paid beginning at the earlier of receipt of Chinese regulatory approval or five years.

This agreement transfers ownership of the SurgiBot System assets, while the Company retains the option to distribute or co-distribute the SurgiBot system outside of China. Upon completion of the transfer of all SurgiBot system assets, GBIL will have the SurgiBot system manufactured in China and obtain Chinese regulatory clearance from the China Food and Drug Administration (“CFDA”), while entering into a nationwide distribution agreement with China National Scientific and Instruments and Materials Company (CSIMC) for the Chinese market.

Balance Sheet

As of December 31, 2017, the Company’s cash and restricted cash balance was approximately $97 million. The Company believes that this capital is sufficient to fund operations through the year 2019.

As of December 31, 2017, there were approximately 199 million shares of common stock outstanding.

About TransEnterix, Inc.

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The Senhance Surgical Robotic System is available for sale in the US, the EU and select other countries. For more information, visit the TransEnterix website at www.transenterix.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether we will be able to build upon our momentum and drive the global adoption of the Senhance in 2018; whether we will deliver and recognize revenue from the sale of a European Senhance System in the 2018 first quarter; whether we will expand the Senhance System US FDA clinical indications to include hernia and gallbladder; whether we will launch a new ultrasonic energy device, whether we will launch a new five-millimeter instrument platform; whether TransEnterix will receive at least $29 million (including minimum royalties) from GBIL; whether GBIL will be able to obtain the necessary clearances to sell the SurgiBot System in China; whether TransEnterix will be able to successfully distribute or co-distribute the SurgiBot System outside of China, and realize revenues beyond the initial consideration and minimum royalties; and whether our cash through December 31, 2017 will be sufficient capital to fund operations through the year 2019. We cannot assure you that our expectations will be realized. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 6, 2017 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

For TransEnterix, Inc.
Investors:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media:
Joanna Rice, + 1 951-751-1858
joanna@greymattermarketing.com


navigation-1-e1507672007846.png

December 22, 2017 OrthoSpineNews

HARTFORD, Conn.Dec. 22, 2017 /PRNewswire/ — Hartford HealthCare (HHC) has pioneered a new, advanced technology at The Hospital of Central Connecticut, which is the first hospital in all of New England to use the new Globus ExcelsiusGPS™, a sophisticated surgical guidance system for spine procedures. The new technology also will soon be available at Backus Hospital.

The ExcelsiusGPS™ brings an even greater level of precision to surgeons performing spine surgery and the patients they serve. The ExcelsiusGPS™ system is the first robotic assisted navigation system that is used by surgeons during the procedure, in real time. It is designed specifically to make surgery safer, and help surgeons ensure implants and hardware placement is even more precise. The technology also enables minimally invasive spine procedures which are often linked to less blood loss, less muscle damage, and a faster recovery.

“We are innovators at Hartford HealthCare, and we have a long history of bringing the latest and most valuable technology to the patients and communities we serve,” said Jeffrey Flaks, Hartford HealthCare President and Chief Operating Officer. “We believe technology is a true partner in care — enabling our talented experts to improve outcomes, enhance quality and deliver an exceptional experience for our patients. This is a fitting next step as we continue to pioneer guidance technology in healthcare.”

Hartford HealthCare is a leader in robotic-assisted surgery, with an extensive surgical robotics program, which is aimed at improving patient outcomes and improving the quality of care. Hartford HealthCare has been using the da Vinci® Surgical System for several years, combining the latest in minimally invasive surgical and robotics technologies to perform successful complex as well as routine surgeries. In March, Hartford HealthCare became the first healthcare system in the state of Connecticut and throughout the Northeast to debut Mazor X robotic-assisted surgical guidance system.

About Hartford HealthCare. Hartford HealthCare is Connecticut’s most comprehensive health care network. Our fully integrated health system includes a tertiary-care teaching hospital, an acute-care community teaching hospital, an acute-care hospital and trauma center, two community hospitals, the state’s most extensive behavioral health services network, a large primary care physician practice group, a regional home care system, an array of senior care services, a coordinated cancer institute with five cancer centers, and a large physical therapy rehabilitation network. Visit us at www.hartfordhealthcare.org.

SOURCE Hartford HealthCare

Related Links

https://hartfordhealthcare.org